| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 10,000 | $353.64 | $3,536,397.68 | -16.7% | -15.8% | +34.9% | |
| Feb 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Klee Justin B.60 | Co-chief Executive Officer | Sell | 11,855 | $3.47 | $41,103.66 | -0.4% | +50.6% | +323.7% | |
| Feb 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 11,851 | $3.47 | $41,107.56 | -0.4% | +50.6% | +323.7% | |
| Feb 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Patel Gautam | Director | Sell | 80,000 | $8.14 | $651,200.00 | -4.1% | -7.8% | +74.2% | |
| Feb 3, 2025 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 2,054 | $35.30 | $72,506.20 | -1.0% | +7.6% | -34.4% | |
| Feb 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina53 | Chief Legal Officer | Sell | 3,678 | $3.49 | $12,839.16 | -2.6% | +50.6% | +323.7% | |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | Butler John P.61 | CEO And President | Sell | 144,250 | $2.10 | $302,925.00 | -2.6% | +10.4% | -33.5% | |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | Burke Steven Keith61 | SVP, Chief Medical Officer | Sell | 50,506 | $2.10 | $106,062.60 | -3.0% | +10.4% | -33.5% | |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | Malabre Richard C69 | SVP, Chief Accounting Officer | Sell | 30,202 | $2.10 | $63,424.20 | -9.7% | +10.4% | -33.5% | |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | Grund Nicholas | Chief Commercial Officer | Sell | 55,621 | $2.10 | $116,804.10 | -11.2% | +10.4% | -33.5% | |
| Feb 3, 2025 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 1,045 | $150.81 | $157,594.39 | -14.2% | -26.9% | -7.4% | |
| Jan 31, 2025 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,250 | $152.91 | $191,133.00 | -3.0% | -29.8% | -10.4% | |
| Jan 31, 2025 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 1,457 | $152.80 | $222,636.16 | -4.3% | -29.8% | -10.4% | |
| Jan 31, 2025 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Executive Officer | Sell | 1,541 | $152.87 | $235,577.45 | -1.1% | -29.8% | -10.4% | |
| Jan 31, 2025 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 1,740 | $152.89 | $266,024.95 | -4.5% | -29.8% | -10.4% | |
| Jan 31, 2025 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 1,283 | $152.87 | $196,135.80 | -3.8% | -29.8% | -10.4% | |
| Jan 31, 2025 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 1,104 | $152.94 | $168,849.40 | -44.6% | -29.8% | -10.4% | |
| Jan 31, 2025 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 1,207 | $152.94 | $184,598.58 | -2.8% | -29.8% | -10.4% | |
| Jan 31, 2025 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 100,000 | $0.18 | $18,000.00 | +7.1% | - | - | |
| Jan 31, 2025 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles56 | Director | Sell | 2,707 | $152.92 | $413,966.89 | -0.5% | -29.8% | -10.4% | |
| Jan 31, 2025 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 100,000 | $35.22 | $3,522,300.00 | -78.2% | -3.0% | -27.3% | |
| Jan 31, 2025 | NBIX Neurocrine Biosciences Inc | Onyia Jude54 | Chief Scientific Officer | Sell | 126 | $152.97 | $19,273.98 | -0.8% | -29.8% | -10.4% | |
| Jan 31, 2025 | BSPK Bespoke Extracts, Inc. | Feinsod Michael | CEO | Buy | 3,000 | $0.11 | $330.00 | - | - | - | |
| Jan 30, 2025 | ALKS Alkermes Plc. | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 100,918 | $32.05 | $3,234,381.53 | -69.5% | -9.8% | +6.2% | |
| Jan 28, 2025 | ETST Earth Science Tech, Inc. | Flores Ernesto L | CFO | Buy | 43,478 | $0.23 | $9,999.94 | +84.4% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.